Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Journal of the American Academy of Dermatology

Volumn 74, Issue 5, 2016, Pages 841-850

  Papp, Kim A ^a   Krueger, James G ^b   Feldman, Steven R ^c   Langley, Richard G ^d   Thaci, Diamant ^e   Torii, Hideshi ^f   Tyring, Stephen ^g   Wolk, Robert ^h   Gardner, Annie ^h   Mebus, Charles ^h   Tan, Huaming ^h   Luo, Yingchun ^h   Gupta, Pankaj ^h   Mallbris, Lotus ⁱ   Tatulych, Svitlana ^h  

^a K Papp Clinical Research and Probity Medical Research   (Canada)

^b ROCKEFELLER UNIVERSITY   (United States)

^c WAKE FOREST BAPTIST HEALTH   (United States)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f KYUSHU HOSPITAL   (Japan)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^h PFIZER INC   (United States)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

Author keywords

efficacy; Janus kinase inhibitor; long term; psoriasis; randomized controlled trial; safety; tofacitinib

Indexed keywords

PLACEBO; TOFACITINIB; JANUS KINASE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ARTHRALGIA; ARTICLE; ASSESSMENT OF HUMANS; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CARCINOMA; FEMALE; HEART ARREST; HEART DISEASE; HEART INFARCTION; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLUENZA; LONG TERM CARE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON MELANOMA SKIN CANCER; OPEN STUDY; OPPORTUNISTIC INFECTION; PANCREAS CARCINOMA; PHASE 3 CLINICAL TRIAL; PHYSICIAN; PHYSICIAN GLOBAL ASSESSMENT; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK REDUCTION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; DOSE RESPONSE; DRUG ADMINISTRATION; EVALUATION STUDY; FOLLOW UP; ORAL DRUG ADMINISTRATION; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; CHRONIC DISEASE; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; JANUS KINASES; MALE; MIDDLE AGED; PATIENT SAFETY; PIPERIDINES; PROTEIN KINASE INHIBITORS; PSORIASIS; PYRIMIDINES; PYRROLES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84963632371     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.01.013     Document Type: Article

References (17)

1. M.K. Ramirez-Fort, A.A. Levin, S.C. Au, and et al. Continuous versus intermittent therapy for moderate-to-severe psoriasis Clin Exp Rheumatol 31 Suppl 2013 S63 S70
2. A.W. Armstrong, A.D. Robertson, J. Wu, and et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011 JAMA Dermatol 149 2013 1180 1185
3. U. Mrowietz, K. Kragballe, K. Reich, and et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus Arch Dermatol Res 303 2011 1 10
4. E.J. Horn, K.M. Fox, V. Patel, and et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey J Am Acad Dermatol 57 2007 957 962
5. P.C. van de Kerkhof, K. Reich, A. Kavanaugh, and et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey J Eur Acad Dermatol Venereol 29 2015 2002 2010
6. K.A. Papp, M.A. Menter, M. Abe, and et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomized, placebo-controlled, phase 3 trials Br J Dermatol 173 2015 949 961
7. H. Bachelez, P.C. van de Kerkhof, R. Strohal, and et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomized non-inferiority trial Lancet 386 2015 552 561
8. J.B. Kelly, P. Foley, and B.E. Strober Current and future oral systemic therapies for psoriasis Dermatol Clin 33 2015 91 109
9. K. Reich, R.G. Langley, K.A. Papp, and et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis N Engl J Med 365 2011 1586 1596
10. G.C. Chaidemenos, O. Mourellou, N. Avgoustinaki, and et al. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis J Eur Acad Dermatol Venereol 21 2007 1203 1208
11. J.H. Rim, J.Y. Park, Y.B. Choe, and et al. The efficacy of calcipotriol + acitretin combination therapy for psoriasis: comparison with acitretin monotherapy Am J Clin Dermatol 4 2003 507 510
12. B.E. Strober Methotrexate and cyclosporine in psoriasis revisited Semin Cutan Med Surg 33 2014 S27 S30
13. A.D. Ormerod, E. Campalani, M.J. Goodfield, and et al. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology Br J Dermatol 162 2010 952 963
14. K. Papp, K. Reich, C.L. Leonardi, and et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) J Am Acad Dermatol 73 2015 37 49
15. R. Bissonnette, L. Iversen, H. Sofen, and et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial Br J Dermatol 172 2015 1395 1406
16. K. Winthrop, M. Lebwohl, A.D. Cohen, and et al. Herpes zoster and tofacitinib therapy in patients with psoriasis J Invest Dermatol 135 2015 S1
17. G. Shalom, D. Zisman, H. Bitterman, and et al. Systemic therapy for psoriasis and the risk of herpes zoster: a 500000 person-year study JAMA Dermatol 151 2015 533 538